Skip to main content

Vaxart, Inc. (VXRT) Stock Forecast 2025 - AI Price Prediction & Analysis


Vaxart, Inc. (VXRT) AI Stock Price Forecast & Investment Analysis

Vaxart, Inc. Stock Price Chart and Technical Analysis

Loading Vaxart, Inc. interactive price chart and technical analysis...

Vaxart, Inc. (VXRT) - Comprehensive Stock Analysis & Investment Research

Deep dive into Vaxart, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Vaxart, Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Vaxart, Inc.: Vaxart, Inc. operates in the Life Sciences sector, making it an emerging small-cap investment.

Vaxart, Inc. (Stock Symbol: VXRT) is a leading company in the Life Sciences sector , specifically operating within the Biological Products, (No Diagnostic Substances) industry.

The organization employs approximately 140 professionals worldwide .

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Vaxart, Inc.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Vaxart, Inc.: With $80M in annual revenue and -382.3% net margin, the company demonstrates developing profitability.

Annual Revenue: $80 million generating a -382.3% net profit margin .

Market Capitalization: $82 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -46.5% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Vaxart, Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Vaxart, Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Vaxart, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Vaxart, Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Vaxart, Inc.: Market positioning analysis based on available financial and operational metrics.

Vaxart, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company maintains a healthy 99.6% gross margin, indicating strong pricing power and operational efficiency.

Vaxart, Inc. (VXRT) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Vaxart, Inc. stock analysis.

Loading Vaxart, Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into Vaxart, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Vaxart, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Vaxart, Inc.: With a P/E ratio of -0.85, the market sees the stock as potentially undervalued.

P/E Ratio -0.85x
P/B Ratio 2.51x
Market Cap $82M
EPS $-0.23
Book Value/Share $0.14
Revenue/Share $0.35
FCF/Share $-0.23
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Vaxart, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Vaxart, Inc.: An ROE of -46.5% indicates room for improvement in shareholder value creation.

ROE -46.5%
ROA -39.2%
ROIC -43.5%
Gross Margin 99.6%
Operating Margin -378.9%
Net Margin -382.3%
EBT Margin -790.5%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Vaxart, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Vaxart, Inc.: A current ratio of 13.97 indicates strong liquidity.

Current Ratio 13.97x
Quick Ratio 13.39x
D/E Ratio 0.07x
Financial Leverage 1.20x
Interest Coverage -57.7x
Working Capital $117M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Vaxart, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Vaxart, Inc.: Free cash flow of $-74M indicates cash challenges that need attention.

Operating Cash Flow $-68M
Free Cash Flow $-74M
Capital Spending $-6M
OCF Growth YoY 542.3%
FCF Growth YoY 540.2%
FCF/Sales -617.2%
CapEx/Sales 578.1%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Vaxart, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Vaxart, Inc.: An asset turnover of 0.01x suggests room for improvement in asset utilization.

Asset Turnover 0.01x
Receivables Turnover 1.2x
Fixed Assets Turnover 0.0x
Days Sales Outstanding 303 days
Payables Period 238 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Vaxart, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Vaxart, Inc.: With annual revenue of $80M, Vaxart, Inc. represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)
Total Revenue $80M
R&D Expense $66M
SG&A Expense $376M
Cost of Goods Sold $-40M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 77%
Cash & Short-term Investments 74%
Total Liabilities 17%
Short-term Debt 5%
Accounts Receivable 0%
Dividend & Shareholder Information
Shares Outstanding 229M
Growth Metrics (YoY)
EPS Growth -29.5%

Latest Vaxart, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Vaxart, Inc. (VXRT) stock price and investment outlook.

, source: Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (VXRT) today announced a change in management. Effective immediately Andrei Floroiu, President and Chief Executive Officer ...

, source: Seeking Alpha

Greetings. Welcome to the Vaxart Business Update and First Quarter 2025 Financial Results Conference Call. A question-and-answer session will follow management's opening remarks. Individual investors ...

, source: Insider Monkey

Operator: Greetings, and welcome to the Vaxart Business Update and Second Quarter 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

, source: Business Insider

Chair Michael J. Finney, Ph.D. to Serve as Interim Chief Executive Officer SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced a change in ...

, source: MarketWatch

Visit a quote page and your recently viewed tickers will be displayed here. Dr. Michael J. Finney is an Independent Chairman at Vaxart, Inc. and a Managing Director at Finney Capital. He is on the ...

Vaxart, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Vaxart, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS Unlock Forecast - 30 Days FREE Trial $123M -1.9x 1.1x
ABP Unlock Forecast - 30 Days FREE Trial $13M x 0.0x
ACLX Unlock Forecast - 30 Days FREE Trial $4689M -74.1x 12.0x
ACOG Unlock Forecast - 30 Days FREE Trial $110M x 3.5x
ADAP Unlock Forecast - 30 Days FREE Trial $318M -13.2x -11.8x
ADMA Unlock Forecast - 30 Days FREE Trial $3621M 17.3x 9.1x
ADPT Unlock Forecast - 30 Days FREE Trial $2621M -4.6x 14.6x
AGEN Unlock Forecast - 30 Days FREE Trial $116M -0.5x -0.5x
AIM Unlock Forecast - 30 Days FREE Trial $2M -0.5x -183.3x
AIMI Unlock Forecast - 30 Days FREE Trial $2M x x
ALEC Unlock Forecast - 30 Days FREE Trial $152M -1.2x 2.1x
ALGS Unlock Forecast - 30 Days FREE Trial $61M -19.2x 0.6x
ALLO Unlock Forecast - 30 Days FREE Trial $264M -1.4x 0.8x
AMGN Unlock Forecast - 30 Days FREE Trial $156228M 23.8x 21.0x
APGE Unlock Forecast - 30 Days FREE Trial $3122M -20.5x 4.3x
APTOF Unlock Forecast - 30 Days FREE Trial $4M x x
ARMP Unlock Forecast - 30 Days FREE Trial $123M -1.0x -1.6x
ARTV Unlock Forecast - 30 Days FREE Trial $132M x 0.9x
ATHA Unlock Forecast - 30 Days FREE Trial $143M -0.2x 4.5x
ATRA Unlock Forecast - 30 Days FREE Trial $103M 17.8x -1.1x
AURA Unlock Forecast - 30 Days FREE Trial $358M -4.9x 2.1x
AUTL Unlock Forecast - 30 Days FREE Trial $407M x 1.2x
AVXL Unlock Forecast - 30 Days FREE Trial $793M -17.3x 8.7x
BCLI Unlock Forecast - 30 Days FREE Trial $7M -4.9x -0.9x
BCRX Unlock Forecast - 30 Days FREE Trial $1511M -12.1x -4.0x
BDTX Unlock Forecast - 30 Days FREE Trial $228M 15.8x 1.7x
BEAM Unlock Forecast - 30 Days FREE Trial $2817M -12.6x 2.7x
BIIB Unlock Forecast - 30 Days FREE Trial $22086M 14.4x 1.5x
CABA Unlock Forecast - 30 Days FREE Trial $261M -1.6x 1.5x
CCCC Unlock Forecast - 30 Days FREE Trial $174M -2.6x 1.0x
CDTX Unlock Forecast - 30 Days FREE Trial $2164M -1.0x 4.3x
CELZ Unlock Forecast - 30 Days FREE Trial $9M -3.4x 1.4x
CERO Unlock Forecast - 30 Days FREE Trial $1M x -196.2x
CGEN Unlock Forecast - 30 Days FREE Trial $176M x 3.5x
CGON Unlock Forecast - 30 Days FREE Trial $3159M x 4.7x
CGTX Unlock Forecast - 30 Days FREE Trial $113M -0.5x 16.1x
CHRS Unlock Forecast - 30 Days FREE Trial $192M 1.1x 1.6x
CLDI Unlock Forecast - 30 Days FREE Trial $5M -0.9x 2.6x
CMPX Unlock Forecast - 30 Days FREE Trial $547M -4.8x 5.9x
CRBU Unlock Forecast - 30 Days FREE Trial $232M -1.5x 1.4x
CRDF Unlock Forecast - 30 Days FREE Trial $148M -4.0x 2.5x
CRIS Unlock Forecast - 30 Days FREE Trial $16M -0.3x -2.9x
CRSP Unlock Forecast - 30 Days FREE Trial $5971M -12.1x 3.5x
CVM Unlock Forecast - 30 Days FREE Trial $47M -0.9x 6.7x
DBVT Unlock Forecast - 30 Days FREE Trial $2111M -3.3x 24.5x
DNLI Unlock Forecast - 30 Days FREE Trial $2325M -8.7x 2.3x
DTIL Unlock Forecast - 30 Days FREE Trial $78M -2.2x 2.3x
ELUT Unlock Forecast - 30 Days FREE Trial $40M -1.4x -0.1x
ENGN Unlock Forecast - 30 Days FREE Trial $414M 3.7x 2.1x
ENTX Unlock Forecast - 30 Days FREE Trial $107M 8.5x 6.2x
ESLA Unlock Forecast - 30 Days FREE Trial $65M -3.1x -16.9x
EXEL Unlock Forecast - 30 Days FREE Trial $10460M 17.1x 5.1x
EXOZ Unlock Forecast - 30 Days FREE Trial $106M x 14.7x
FATE Unlock Forecast - 30 Days FREE Trial $169M -1.3x 0.7x
FDMT Unlock Forecast - 30 Days FREE Trial $530M -3.0x 1.3x
FENC Unlock Forecast - 30 Days FREE Trial $229M 1758.3x -39.7x
FNCH Unlock Forecast - 30 Days FREE Trial $19M -0.1x 1.4x
FTII Unlock Forecast - 30 Days FREE Trial $3M x -0.7x
FTIIU Unlock Forecast - 30 Days FREE Trial $-26M x -0.8x
GILD Unlock Forecast - 30 Days FREE Trial $148785M 23.8x 7.6x
GLUE Unlock Forecast - 30 Days FREE Trial $555M 23.0x 2.1x
GNTA Unlock Forecast - 30 Days FREE Trial $58M x 4.7x
GPLB Unlock Forecast - 30 Days FREE Trial $1M x x
HALO Unlock Forecast - 30 Days FREE Trial $7781M 14.0x 23.4x
HLVX Unlock Forecast - 30 Days FREE Trial $105M -0.6x 0.7x
HUMA Unlock Forecast - 30 Days FREE Trial $267M -3.3x 66.0x
IBRX Unlock Forecast - 30 Days FREE Trial $2262M -3.6x -4.1x
IKT Unlock Forecast - 30 Days FREE Trial $115M -1.0x 1.4x
IMCR Unlock Forecast - 30 Days FREE Trial $1668M x 4.3x
IMVT Unlock Forecast - 30 Days FREE Trial $3240M -14.5x 5.3x
INBX Unlock Forecast - 30 Days FREE Trial $829M -6.8x 12.1x
INKT Unlock Forecast - 30 Days FREE Trial $56M -1.5x -1.4x
INMB Unlock Forecast - 30 Days FREE Trial $49M -2.5x 1.7x
INTS Unlock Forecast - 30 Days FREE Trial $7M -2.2x 3.1x
IOVA Unlock Forecast - 30 Days FREE Trial $754M -4.5x 1.1x
IPSC Unlock Forecast - 30 Days FREE Trial $50M -0.7x 0.2x
IVVD Unlock Forecast - 30 Days FREE Trial $268M -0.4x 6.3x
JSPR Unlock Forecast - 30 Days FREE Trial $40M -3.2x 1.7x
KLRS Unlock Forecast - 30 Days FREE Trial $87M x 1.6x
KLTO Unlock Forecast - 30 Days FREE Trial $32M x 3.0x
KOD Unlock Forecast - 30 Days FREE Trial $961M -2.5x 13.7x
KRYS Unlock Forecast - 30 Days FREE Trial $5384M 36.7x 5.2x
KYMR Unlock Forecast - 30 Days FREE Trial $4132M -17.8x 4.3x
KYTX Unlock Forecast - 30 Days FREE Trial $287M x 1.6x
LADX Unlock Forecast - 30 Days FREE Trial $0M x x
LCTX Unlock Forecast - 30 Days FREE Trial $369M -4.7x 7.6x
LENZ Unlock Forecast - 30 Days FREE Trial $911M -6.7x 4.4x
LIMN Unlock Forecast - 30 Days FREE Trial $0M x x
LXEO Unlock Forecast - 30 Days FREE Trial $517M -0.4x 3.7x
MAZE Unlock Forecast - 30 Days FREE Trial $1311M x 5.0x
MGTX Unlock Forecast - 30 Days FREE Trial $701M -3.4x 237.0x
MGX Unlock Forecast - 30 Days FREE Trial $108M x 0.6x
MRNA Unlock Forecast - 30 Days FREE Trial $10402M -3.2x 1.1x
NBIX Unlock Forecast - 30 Days FREE Trial $14256M 40.8x 5.3x
NMRA Unlock Forecast - 30 Days FREE Trial $280M -3.9x 1.5x
NVAX Unlock Forecast - 30 Days FREE Trial $1356M 3.2x 36.0x
PASG Unlock Forecast - 30 Days FREE Trial $26M -0.6x 0.7x
PCVX Unlock Forecast - 30 Days FREE Trial $5482M -20.4x 1.8x
PHGE Unlock Forecast - 30 Days FREE Trial $15M 1.5x 0.8x
PLUR Unlock Forecast - 30 Days FREE Trial $34M -1.4x -9.1x
PLX Unlock Forecast - 30 Days FREE Trial $144M 23.0x 2.9x
PRME Unlock Forecast - 30 Days FREE Trial $717M -1.5x 11.8x
PROK Unlock Forecast - 30 Days FREE Trial $197M x 0.0x
QGEN Unlock Forecast - 30 Days FREE Trial $11083M x 3.1x
QNCX Unlock Forecast - 30 Days FREE Trial $100M -1.7x 8.5x
RGEN Unlock Forecast - 30 Days FREE Trial $9357M 8219.1x 4.5x
RGNX Unlock Forecast - 30 Days FREE Trial $657M -1.8x 3.1x
RLAY Unlock Forecast - 30 Days FREE Trial $1178M -2.0x 1.8x
RVMD Unlock Forecast - 30 Days FREE Trial $10182M -11.1x 5.5x
RXRX Unlock Forecast - 30 Days FREE Trial $2614M -4.7x 2.8x
SANA Unlock Forecast - 30 Days FREE Trial $1232M -2.1x 10.1x
SCLX Unlock Forecast - 30 Days FREE Trial $90M -0.4x -0.3x
SCNI Unlock Forecast - 30 Days FREE Trial $8479M -287.8x 1079.1x
SGMO Unlock Forecast - 30 Days FREE Trial $153M -1.6x 7.8x
SLXN Unlock Forecast - 30 Days FREE Trial $2M x 17.0x
SRRK Unlock Forecast - 30 Days FREE Trial $2849M -18.5x 12.2x
SRZN Unlock Forecast - 30 Days FREE Trial $116M -0.5x 2.5x
STRO Unlock Forecast - 30 Days FREE Trial $86M -1.0x -2.5x
TARA Unlock Forecast - 30 Days FREE Trial $212M -2.1x 1.5x
TARS Unlock Forecast - 30 Days FREE Trial $2788M -12.4x 8.4x
TCBPY Unlock Forecast - 30 Days FREE Trial $13M x 11.8x
TCRX Unlock Forecast - 30 Days FREE Trial $300M -4.6x 1.7x
TECX Unlock Forecast - 30 Days FREE Trial $331M -8.9x 1.2x
TNYA Unlock Forecast - 30 Days FREE Trial $247M -2.5x 2.5x
TRML Unlock Forecast - 30 Days FREE Trial $1232M -3.5x 4.8x
TSHA Unlock Forecast - 30 Days FREE Trial $1295M -3.0x 5.2x
TVGN Unlock Forecast - 30 Days FREE Trial $136M x -29.3x
TWST Unlock Forecast - 30 Days FREE Trial $2053M -12.6x 4.3x
VACH Unlock Forecast - 30 Days FREE Trial $66M x 0.0x
VACHU Unlock Forecast - 30 Days FREE Trial $67M x 0.0x
VCEL Unlock Forecast - 30 Days FREE Trial $1832M 257.8x 6.0x
VIR Unlock Forecast - 30 Days FREE Trial $831M -2.0x 0.9x
VOR Unlock Forecast - 30 Days FREE Trial $3644M -0.6x 3.9x
VXRT Unlock Forecast - 30 Days FREE Trial $82M -0.9x 2.5x
VYGR Unlock Forecast - 30 Days FREE Trial $258M 570.6x 1.1x
ZIVO Unlock Forecast - 30 Days FREE Trial $48M -31.3x -2.0x

Frequently Asked Questions - Vaxart, Inc. Stock Forecast

How accurate are Vaxart, Inc. stock predictions?

Our AI model shows a 58% Spearman correlation coefficient for VXRT predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Vaxart, Inc. stock price forecasts?

Our analysis considers Vaxart, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Vaxart, Inc. a good investment in 2025?

Based on our AI analysis, Vaxart, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Vaxart, Inc. forecasts updated?

Vaxart, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Vaxart, Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Vaxart, Inc. stock.

My Portfolio

Investment Dashboard

Loading your portfolio...